Heramed Limited Reports Expiry of 30.4 Million HMDAZ Options Unexercised, Adjusting Capital Structure

Heramed Limited’s Capital Structure and Securities Overview

As an ASX-listed entity, Heramed Limited manages a diversified capital structure including 1,158,636,602 fully paid ordinary shares currently on issue. The company also holds multiple series of unquoted options and performance rights issued through capital management and employee incentive programs. These convertible securities provide flexibility in compensation and retention strategies across various corporate initiatives.

The issuance of multiple option tranches with distinct exercise prices and expiry dates reflects Heramed’s phased approach to equity incentivization and capital deployment. The recent expiration of the HMDAZ tranche aligns with the typical lifecycle of convertible securities, where some options lapse unexercised due to evolving market conditions and company performance.

Details on HMDAZ Option Expiry and Process

The HMDAZ options, unquoted equity instruments with a $0.12 exercise price, expired on 20 July 2026 without being exercised or converted into ordinary shares. This automatic expiry on the scheduled date is a standard corporate event marking the end of the contractual life of these securities. Heramed did not pay any consideration to option holders upon expiry, consistent with standard practice for unexercised options.

The non-exercise of these options indicates that Heramed’s share price did not exceed the $0.12 strike price during the options’ term, or that holders opted not to convert for economic reasons. The announcement focuses on regulatory disclosure requirements and does not comment on market conditions or holder decisions. The expiry reduces the outstanding unquoted convertible securities on Heramed’s register.

Impact on Issued Capital and Remaining Convertible Securities

Following the HMDAZ options expiry, Heramed’s issued capital reflects the removal of these 30.4 million options. The ordinary share register remains steady at 1,158,636,602 shares, confirming no impact on the company’s equity base. However, Heramed continues to hold a significant portfolio of other unquoted convertible securities, including:

• 3 million HMDAA options expiring January 2030 at $0.0528 exercise price
• 750,000 HMDAAC options expiring January 2027 at $0.023 exercise price
• 70 million HMDAAG options expiring December 2028 at $0.02 exercise price
• 15 million HMDAAD options expiring March 2027 at $0.045 exercise price
• Approximately 177 million options across all unquoted tranches
• 26,898,420 performance rights under the HMDAAH code

This complex capital structure indicates Heramed’s ongoing use of equity-based compensation and incentive mechanisms across management and staff.

Upcoming Option Expiries and Portfolio Outlook

With HMDAZ options expired, the next unquoted options set to expire are 750,000 HMDAAC options on 23 January 2027 at a $0.023 exercise price, followed by 350,000 HMDAY options expiring 27 January 2027 at $0.15, and 15 million HMDAAD options expiring 11 March 2027 at $0.045. These near-term expiries likely correspond to securities issued to founders, early investors, or employees during growth phases.

Longer-dated options include the 70 million HMDAAG options expiring 24 December 2028 at $0.02, the largest single tranche, alongside 17 million HMDAAE and 19 million HMDAAC options expiring in 2028 and 2029 respectively. Investors should monitor these expiries for potential conversion activity or share price impacts if market conditions favor exercise.

Regulatory Disclosure and ASX Compliance

Heramed’s ASX notification of HMDAZ option cessation complies with Corporations Act and ASX Listing Rules requirements. Listed companies must disclose changes to issued capital, including option expiries, cancellations, or conversions, to maintain market transparency regarding securities capable of diluting shareholders.

The Appendix 3H form submitted details the security code, description, number ceased, cessation reason, and date, alongside updated capital tables. This transparent reporting enables investors and analysts to accurately track Heramed’s capital structure.

Exercise Price Context and Share Price Performance

The $0.12 exercise price of HMDAZ options provides insight into Heramed’s share price environment at grant. The lapse of 30.4 million options unexercised suggests the share price did not surpass this level during their term. Comparatively, most remaining options have lower exercise prices between $0.02 and $0.045, indicating possible downward valuation adjustments or later-stage capital management issuances. Performance rights (HMDAAH) vest based on performance criteria rather than share price.

Shareholder Implications and Dilution Considerations

The expiry of unexercised options generally benefits existing shareholders by eliminating potential dilution. The removal of 30.4 million HMDAZ options removes a theoretical source of future share dilution. However, Heramed’s remaining approximately 177 million unquoted options and 26.9 million performance rights still pose dilution risk if exercised or vested, dependent on share price and performance outcomes. Investors should consider this latent dilution in their equity assessments.

Capital Management and Equity Incentive Strategy

Heramed’s layered issuance of options and performance rights reflects a strategic approach to align management and employee interests with shareholder value creation. Staggered option tranches with varying prices and expiries support talent retention while managing dilution. Unexercised options like HMDAZ represent cases where incentive conditions were unmet or holders departed.

The combination of options and performance rights indicates a comprehensive equity compensation framework linking rewards to both market performance and specific corporate milestones, underscoring the company’s focus on incentivizing long-term value creation.

Financial Impact and Market Reaction

The announcement confirms no financial consideration was paid by Heramed for the HMDAZ options expiry, consistent with standard option lapse procedures. This event has no immediate cash flow impact. Public information does not indicate a significant share price reaction around the 20 July 2026 expiry date, as option expiries are typically routine administrative matters unless accompanied by broader market developments.

Investors interested in Heramed’s share price trends during this period should review trading data and company disclosures for comprehensive context.